secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEXGEL, INC. (NXGL)
CIK:        0001468929
Form:       8-K
Filed at:   2026-08-17T12:15:29+00:00
Accession:  0001493152-26-038637
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NexGel Q2 2026: revenue $3.69M, net loss $2.87M; BioNX backlog $795K; proxy vote fails
--------------------------------------------------------------------------------

- Q2 revenue $3.69M, net loss $2.87M; includes $756,554 BioNX amortization, $273,710 transaction costs, $144,495 SilverSeal recall.
- BioNX Surgical backlog ~$795K due to supply chain; Sequence transferring manufacturing to San Antonio, TX.
- Proxy vote failed to increase authorized shares/reverse split; will resolicit standalone, engaged Alliance Advisors, target late Sept.
- $710K restricted cash from ATW Partners released and returned post-quarter; relationship concluded.
- Launched BioNX Regenerative Eye Health & Aesthetics, led by Shaun Mullen; SilverSeal recall supports hospital launch in August.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468929/000149315226038637/0001493152-26-038637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468929/000149315226038637/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-038637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer